16 GHP International Life Sciences Awards 2022 iRhythm Technologies’ work helps save lives. It has created an innovative service – Zio XT – which optimises and transforms the data it collects into clinically actionable information.The service was designed with the aim to improve the detection of cardiac arrythmias and, in turn, help clinicians make a faster and more accurate diagnosis. The way in which cardiac arrhythmias are diagnosed is being redefined. Digital healthcare company iRhythm Technologies Ltd has brought forth an innovative service – Zio XT. With the help of a propriety AI algorithm, Zio combines a patented wearable biosensor with AI based data analytics to transform data from millions of heartbeats into clinically actionable information. The device has been designed with patients in mind, and as a result, it can be worn continuously for up to 14 days whilst minimising disruption to patients’ daily activities. iRhythm Technologies was founded with the objective to improve arrythmia detection on a global scale, and consequently, the company believes that data quality and quantity has the potential to alter clinical management of patients. Moreover, iRhythm Technologies works in collaboration with healthcare teams and hospital systems to enhance workflows and decrease inefficiencies. As a result of iRhythm Technologies’ exceptional efforts, clinical professionals can now identify and diagnose patients more quickly and precisely than ever before. Zio XT was designed to maximise quality data collection, giving clinicians a fuller picture of their patients’ heart rhythm, while disruption to daily activities have been kept to a significant low. Research undertaken by iRhythm has found that 98% of patients comply with the prescribed wear time1, and in a direct head to head patients preferred wearing Zio for 14 days rather a Holter for only 24 hours2. 99% of clinicians agree with the finding in the Zio report1, providing clinicians with a trusted solution to help diagnose accurately the first time of monitoring. Indeed, iRhythm Technologies prides itself on its drive for progress – it is constantly striving to innovate and improve. It entered the UK market in 2016 after a great amount of success in the US. Tash Brown, UK Product Marketing Manager, explains, ‘2014 research conducted by the British Heart Foundation found that 5,145 people aged between 45-54 died as a result of cardiovascular disease a year, in comparison to 4,954 from the same age bracket in 2012. As a company, we knew we had a solution that solved an unmet need in the NHS, and we continue to make strides towards reducing the devastating impact that cardiovascular disease can have.’ Of course, this makes the company enormously unique. It has been repeatedly recognised for its contributions to the healthcare field, especially by the Accelerated Access Collaborate (AAC) as part of the NHS AI Lab with the National Institute for Health Research. In 2020, it was awarded the Artificial Intelligence in Health and Care Award by the aforementioned organisations, which then provided iRhythm Technologies with funding to evaluate Zio XT for real world clinical, operational, and financial benefits at selected NHS trusts. However, as these evaluations are drawing to a close, iRhythm Technologies is facing a new challenge; how will the NHS fund and support the implementation of Zio XT system wide? Tash discloses, ‘initial outcomes from implementing Zio at scale have been hugely positive, so we are working closely with trusts to showcase the “value” our service brings across a patient pathway, creating a long-term sustainable service in the NHS. As hospital systems look to procure proven innovations through valuebased mechanisms rather than just “cost”, we are partnering with stakeholders to navigate the changing NHS landscape.’ iRhythm Technologies’ benefits have been widely documented, including in the case of one patient, who was fitted with the device as part of the NHSX AI in Health and Care Award. On the 10th day of recording, the patient’s heart stopped beating for 28 seconds whilst they slept. The data was reviewed by one of iRhythm’s highly specialised cardiac physiologists and the patient’s clinician was notified. The patient was brought in to the hospital where they were fitted with a pacemaker and the condition was treated effectively. Holter monitoring typically only take places over a 24 or 48-hour time period. This is, in turn, a primary example as to how longer term monitoring with iRhythm Technologies’ Zio XT can – and does – help save lives. As such, the company’s plans involve the continued support of patients and staff throughout the NHS, and it hopes that its work won’t only be seen as a case study, but also as a catalyst for long term commissioning throughout the NHS framework. Contact: Tash Brown Company: iRhythm Technologies Ltd Web Address: https://irhythmtech.co.uk/ Best Ambulatory Cardiac Monitoring Solution 2022: Zio® by iRhythm Jul22144 1) Data on file, iRhythm Technologies, 2019 2) Barrett, et al., Comparison of 24-hour Holter Monitoring with 14-day Novel Adhesive Patch Electrocardiographic Monitoring. American Journal of Medicine, 2014.